
M Lipsitch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7901376/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study. Lancet Infectious Diseases, The, 2022, 22, 357-366.	9.1	79
2	Indirect protection of children from SARS-CoV-2 infection through parental vaccination. Science, 2022, 375, 1155-1159.	12.6	39
3	Identifying and Alleviating Bias Due to Differential Depletion of Susceptible People in Postmarketing Evaluations of COVID-19 Vaccines. American Journal of Epidemiology, 2022, 191, 800-811.	3.4	53
4	Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ, The, 2022, 376, e068414.	6.0	105
5	SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nature Reviews Immunology, 2022, 22, 57-65.	22.7	217
6	Antibiotic prescribing across age groups in the Kaiser Permanente Northern California population in association with different diagnoses, and with influenza incidence, 2010-2018. Epidemiology and Infection, 2022, 150, 1-25.	2.1	1
7	Near real-time surveillance of the SARS-CoV-2 epidemic with incomplete data. PLoS Computational Biology, 2022, 18, e1009964.	3.2	8
8	Analysis of multiple bacterial species and antibiotic classes reveals large variation in the association between seasonal antibiotic use and resistance. PLoS Biology, 2022, 20, e3001579.	5.6	12
9	Deep-sequence phylogenetics to quantify patterns of HIV transmission in the context of a universal testing and treatment trial – BCPP/Ya Tsie trial. ELife, 2022, 11, .	6.0	12
10	Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. New England Journal of Medicine, 2022, 386, 1603-1614.	27.0	213
11	Wrong question and the wrong standard of proof. Journal of Medical Ethics, 2022, , medethics-2022-108320.	1.8	1
12	Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. Open Forum Infectious Diseases, 2022, 9, .	0.9	5
13	BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age. New England Journal of Medicine, 2022, 387, 227-236.	27.0	68
14	On the Effect of Age on the Transmission of SARS-CoV-2 in Households, Schools, and the Community. Journal of Infectious Diseases, 2021, 223, 362-369.	4.0	257
15	Potential Biases Arising From Epidemic Dynamics in Observational Seroprotection Studies. American Journal of Epidemiology, 2021, 190, 328-335.	3.4	11
16	Nowcasting for Real-Time COVID-19 Tracking in New York City: An Evaluation Using Reportable Disease Data From Early in the Pandemic. JMIR Public Health and Surveillance, 2021, 7, e25538.	2.6	23
17	Negative frequency-dependent selection and asymmetrical transformation stabilise multi-strain bacterial population structures. ISME Journal, 2021, 15, 1523-1538.	9.8	17
18	Estimating internationally imported cases during the early COVID-19 pandemic. Nature Communications, 2021, 12, 311.	12.8	35

#	Article	IF	CITATIONS
19	The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials. JAMA - Journal of the American Medical Association, 2021, 325, 219.	7.4	31
20	How to Test Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines Ethically Even After One Is Available. Clinical Infectious Diseases, 2021, 73, 2332-2334.	5.8	9
21	Antibiotic Use and Presumptive Pathogens in the Veterans Affairs Healthcare System. Clinical Infectious Diseases, 2021, , .	5.8	3
22	Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science, 2021, 371, 916-921.	12.6	588
23	How to detect and reduce potential sources of biases in studies of SARS-CoV-2 and COVID-19. European Journal of Epidemiology, 2021, 36, 179-196.	5.7	93
24	Burden of Antimicrobial Resistance: Compared to What?. Epidemiologic Reviews, 2021, 43, 53-64.	3.5	24
25	Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure. Clinical Microbiology and Infection, 2021, 27, 372-377.	6.0	10
26	BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. New England Journal of Medicine, 2021, 384, 1412-1423.	27.0	2,179
27	Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination. Nature Reviews Immunology, 2021, 21, 330-335.	22.7	98
28	Modeling the impact of racial and ethnic disparities on COVID-19 epidemic dynamics. ELife, 2021, 10, .	6.0	22
29	Leveraging Pathogen Sequence and Contact Tracing Data to Enhance Vaccine Trials in Emerging Epidemics. Epidemiology, 2021, 32, 698-704.	2.7	3
30	Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ, The, 2021, 373, n1098.	6.0	267
31	Estimating the cumulative incidence of COVID-19 in the United States using influenza surveillance, virologic testing, and mortality data: Four complementary approaches. PLoS Computational Biology, 2021, 17, e1008994.	3.2	28
32	Interpreting vaccine efficacy trial results for infection and transmission. Vaccine, 2021, 39, 4082-4088.	3.8	55
33	Estimating epidemiologic dynamics from cross-sectional viral load distributions. Science, 2021, 373, .	12.6	148
34	Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization. Vaccine, 2021, 39, 4013-4024.	3.8	110
35	Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. New England Journal of Medicine, 2021, 385, 1474-1484.	27.0	1,162
36	Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel. Lancet Regional Health - Europe, The, 2021, 7, 100150.	5.6	101

#	Article	IF	CITATIONS
37	Estimating Vaccine Efficacy Against Transmission via Effect on Viral Load. Epidemiology, 2021, 32, 820-828.	2.7	9
38	Assessing the feasibility of Nipah vaccine efficacy trials based on previous outbreaks in Bangladesh. Vaccine, 2021, 39, 5600-5606.	3.8	11
39	Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. New England Journal of Medicine, 2021, 385, 1078-1090.	27.0	735
40	Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nature Medicine, 2021, 27, 1693-1695.	30.7	222
41	Big data and simple models used to track the spread of COVID-19 in cities. Nature, 2021, 589, 26-28.	27.8	15
42	Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents. New England Journal of Medicine, 2021, 385, 2101-2103.	27.0	82
43	Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet, The, 2021, 398, 2093-2100.	13.7	748
44	Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape. Cell, 2021, 184, 6229-6242.e18.	28.9	72
45	Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study. EClinicalMedicine, 2021, 42, 101190.	7.1	22
46	Depletion-of-susceptibles Bias in Analyses of Intra-season Waning of Influenza Vaccine Effectiveness. Clinical Infectious Diseases, 2020, 70, 1484-1486.	5.8	26
47	Novel methods for the analysis of stepped wedge cluster randomized trials. Statistics in Medicine, 2020, 39, 815-844.	1.6	17
48	The Use of Test-negative Controls to Monitor Vaccine Effectiveness. Epidemiology, 2020, 31, 43-64.	2.7	102
49	Understanding COVID-19 vaccine efficacy. Science, 2020, 370, 763-765.	12.6	200
50	Cross-reactive memory T cells and herd immunity to SARS-CoV-2. Nature Reviews Immunology, 2020, 20, 709-713.	22.7	229
51	Reply to Hasford and to Spinola et al. Journal of Infectious Diseases, 2020, 222, 1574-1575.	4.0	0
52	Statistical Properties of Stepped Wedge Cluster-Randomized Trials in Infectious Disease Outbreaks. American Journal of Epidemiology, 2020, 189, 1324-1332.	3.4	7
53	Testing COVID-19 therapies to prevent progression of mild disease. Lancet Infectious Diseases, The, 2020, 20, 1367.	9.1	12
54	Macrolide and Nonmacrolide Resistance with Mass Azithromycin Distribution. New England Journal of Medicine, 2020, 383, 1941-1950.	27.0	93

#	Article	IF	CITATIONS
55	Opinion: It's ethical to test promising coronavirus vaccines against less-promising ones. Proceedings of the United States of America, 2020, 117, 18898-18901.	7.1	1
56	Reopening Primary Schools during the Pandemic. New England Journal of Medicine, 2020, 383, 981-985.	27.0	142
57	Good science is good science: we need specialists, not sects. European Journal of Epidemiology, 2020, 35, 519-522.	5.7	1
58	Determinants of Staphylococcus aureus carriage in the developing infant nasal microbiome. Genome Biology, 2020, 21, 301.	8.8	11
59	Lockdown measures and relative changes in the age-specific incidence of SARS-CoV-2 in Spain. Epidemiology and Infection, 2020, 148, e268.	2.1	5
60	The role of "spillover―in antibiotic resistance. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29063-29068.	7.1	27
61	Proposed Changes to U.S. Policy on Potential Pandemic Pathogen Oversight and Implementation. MSphere, 2020, 5, .	2.9	5
62	Estimated Demand for US Hospital Inpatient and Intensive Care Unit Beds for Patients With COVID-19 Based on Comparisons With Wuhan and Guangzhou, China. JAMA Network Open, 2020, 3, e208297.	5.9	94
63	Estimating the contribution of different age strata to vaccine serotype pneumococcal transmission in the pre vaccine era: a modelling study. BMC Medicine, 2020, 18, 129.	5.5	29
64	Response to Dawson et al. Journal of Infectious Diseases, 2020, 222, 516-517.	4.0	2
65	Estimating case fatality rates of COVID-19. Lancet Infectious Diseases, The, 2020, 20, 775.	9.1	43
66	Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nature Medicine, 2020, 26, 506-510.	30.7	1,067
67	Aggregated mobility data could help fight COVID-19. Science, 2020, 368, 145-146.	12.6	303
68	Identifying Locations with Possible Undetected Imported Severe Acute Respiratory Syndrome Coronavirus 2 Cases by Using Importation Predictions. Emerging Infectious Diseases, 2020, 26, 1465-1469.	4.3	32
69	The relation between prescribing of different antibiotics and rates of mortality with sepsis in US adults. BMC Infectious Diseases, 2020, 20, 169.	2.9	6
70	Defining the Epidemiology of Covid-19 — Studies Needed. New England Journal of Medicine, 2020, 382, 1194-1196.	27.0	986
71	Response to Cioffi. Journal of Infectious Diseases, 2020, 222, 169-170.	4.0	6
72	Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure. Journal of Infectious Diseases, 2020, 221, 1752-1756.	4.0	186

#	Article	IF	CITATIONS
73	Using Genetic Distance from Archived Samples for the Prediction of Antibiotic Resistance in Escherichia coli. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	5
74	Antibody testing will enhance the power and accuracy of COVID-19-prevention trials. Nature Medicine, 2020, 26, 818-819.	30.7	45
75	Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science, 2020, 368, 860-868.	12.6	2,103
76	Using observational data to quantify bias of traveller-derived COVID-19 prevalence estimates in Wuhan, China. Lancet Infectious Diseases, The, 2020, 20, 803-808.	9.1	58
77	Nowcasting by Bayesian Smoothing: A flexible, generalizable model for real-time epidemic tracking. PLoS Computational Biology, 2020, 16, e1007735.	3.2	79
78	Horizontal gene transfer rate is not the primary determinant of observed antibiotic resistance frequencies in <i>Streptococcus pneumoniae</i> . Science Advances, 2020, 6, eaaz6137.	10.3	19
79	Frequency-dependent selection can forecast evolution in Streptococcus pneumoniae. PLoS Biology, 2020, 18, e3000878.	5.6	24
80	Practical considerations for measuring the effective reproductive number, Rt. PLoS Computational Biology, 2020, 16, e1008409.	3.2	343
81	Temporal rise in the proportion of younger adults and older adolescents among coronavirus disease (COVID-19) cases following the introduction of physical distancing measures, Germany, March to April 2020. Eurosurveillance, 2020, 25, .	7.0	39
82	Potential impact of outpatient stewardship interventions on antibiotic exposures of common bacterial pathogens. ELife, 2020, 9, .	6.0	10
83	Targeted surveillance strategies for efficient detection of novel antibiotic resistance variants. ELife, 2020, 9, .	6.0	6
84	Frequency-dependent selection can forecast evolution in Streptococcus pneumoniae. , 2020, 18, e3000878.		0
85	Frequency-dependent selection can forecast evolution in Streptococcus pneumoniae. , 2020, 18, e3000878.		0
86	Frequency-dependent selection can forecast evolution in Streptococcus pneumoniae. , 2020, 18, e3000878.		0
87	Frequency-dependent selection can forecast evolution in Streptococcus pneumoniae. , 2020, 18, e3000878.		0
88	Frequency-dependent selection can forecast evolution in Streptococcus pneumoniae. , 2020, 18, e3000878.		0
89	Frequency-dependent selection can forecast evolution in Streptococcus pneumoniae. , 2020, 18, e3000878.		0
90	Regulating impact on bystanders in clinical trials: An unsettled frontier. Clinical Trials, 2019, 16, 450-454.	1.6	8

#	Article	IF	CITATIONS
91	Comment on: â€~Antibiotic footprint' as a communication tool to aid reduction of antibiotic consumption. Journal of Antimicrobial Chemotherapy, 2019, 74, 3404-3406.	3.0	3
92	Enhancing Situational Awareness to Prevent Infectious Disease Outbreaks from Becoming Catastrophic. Current Topics in Microbiology and Immunology, 2019, 424, 59-74.	1.1	21
93	Postexposure Effects of Vaccines on Infectious Diseases. Epidemiologic Reviews, 2019, 41, 13-27.	3.5	25
94	Surveillance to maintain the sensitivity of genotype-based antibiotic resistance diagnostics. PLoS Biology, 2019, 17, e3000547.	5.6	15
95	Influenza A Hemagglutinin Passage Bias Sites and Host Specificity Mutations. Cells, 2019, 8, 958.	4.1	6
96	Levels of outpatient prescribing for four major antibiotic classes and rates of septicemia hospitalization in adults in different US states - a statistical analysis. BMC Public Health, 2019, 19, 1138.	2.9	3
97	Modelling the epidemiologic impact of achieving UNAIDS fast-track 90-90-90 and 95-95-95 targets in South Africa. Epidemiology and Infection, 2019, 147, e122.	2.1	11
98	On the role of different age groups during pertussis epidemics in California, 2010 and 2014. Epidemiology and Infection, 2019, 147, e184.	2.1	7
99	On the evolutionary ecology of multidrug resistance in bacteria. PLoS Pathogens, 2019, 15, e1007763.	4.7	54
100	Resistance diagnostics as a public health tool to combat antibiotic resistance: A model-based evaluation. PLoS Biology, 2019, 17, e3000250.	5.6	33
101	Antimicrobial resistance prevalence, rates of hospitalization with septicemia and rates of mortality with sepsis in adults in different US states. International Journal of Antimicrobial Agents, 2019, 54, 23-34.	2.5	35
102	Limited available evidence supports theoretical predictions of reduced vaccine efficacy at higher exposure dose. Scientific Reports, 2019, 9, 3203.	3.3	18
103	Herd immunity alters the conditions for performing dose schedule comparisons: an individual-based model of pneumococcal carriage. BMC Infectious Diseases, 2019, 19, 227.	2.9	6
104	THE AUTHORS REPLY. American Journal of Epidemiology, 2019, 188, 807-808.	3.4	1
105	Case-based surveillance of antimicrobial resistance with full susceptibility profiles. JAC-Antimicrobial Resistance, 2019, 1, dlz070.	2.1	19
106	Mathematical modelling for antibiotic resistance control policy: do we know enough?. BMC Infectious Diseases, 2019, 19, 1011.	2.9	37
107	Hospitalizations Associated with Respiratory Syncytial Virus and Influenza in Children, Including Children Diagnosed with Asthma. Epidemiology, 2019, 30, 918-926.	2.7	18
108	Depletion-of-susceptibles bias in influenza vaccine waning studies: how to ensure robust results. Epidemiology and Infection, 2019, 147, e306.	2.1	36

#	Article	IF	CITATIONS
109	Azithromycin Susceptibility Among <i>Neisseria gonorrhoeae</i> Isolates and Seasonal Macrolide Use. Journal of Infectious Diseases, 2019, 219, 619-623.	4.0	41
110	Challenges of Vaccine Effectiveness and Waning Studies. Clinical Infectious Diseases, 2019, 68, 1631-1633.	5.8	41
111	Models of immune selection for multi-locus antigenic diversity of pathogens. Nature Reviews Immunology, 2019, 19, 55-62.	22.7	23
112	The Relative Impact of Community and Hospital Antibiotic Use on the Selection of Extended-spectrum Beta-lactamase–producing Escherichia coli. Clinical Infectious Diseases, 2019, 69, 182-188.	5.8	23
113	Analyzing Vaccine Trials in Epidemics With Mild and Asymptomatic Infection. American Journal of Epidemiology, 2019, 188, 467-474.	3.4	23
114	Population genomics of pneumococcal carriage in Massachusetts children following introduction of PCV-13. Microbial Genomics, 2019, 5, .	2.0	12
115	Interaction Patterns of Men Who Have Sex With Men on a Geosocial Networking Mobile App in Seven United States Metropolitan Areas: Observational Study. Journal of Medical Internet Research, 2019, 21, e13766.	4.3	5
116	Response to comment on 'The distribution of antibiotic use and its association with antibiotic resistance'. ELife, 2019, 8, .	6.0	1
117	Competing Effects of Indirect Protection and Clustering on the Power of Cluster-Randomized Controlled Vaccine Trials. American Journal of Epidemiology, 2018, 187, 1763-1771.	3.4	17
118	Serotype-specific immune responses to pneumococcal conjugate vaccine among children are significantly correlated by individual: Analysis of randomized controlled trial data. Vaccine, 2018, 36, 473-478.	3.8	11
119	Weak Epistasis May Drive Adaptation in Recombining Bacteria. Genetics, 2018, 208, 1247-1260.	2.9	51
120	On the Relative Role of Different Age Groups During Epidemics Associated With Respiratory Syncytial Virus. Journal of Infectious Diseases, 2018, 217, 238-244.	4.0	34
121	Estimating the proportion of bystander selection for antibiotic resistance among potentially pathogenic bacterial flora. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11988-E11995.	7.1	141
122	Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12911-12919.	7.1	107
123	Microbiome as a tool and a target in the effort to address antimicrobial resistance. Proceedings of the United States of America, 2018, 115, 12902-12910.	7.1	72
124	Use of an individual-based model of pneumococcal carriage for planning a randomized trial of a whole-cell vaccine. PLoS Computational Biology, 2018, 14, e1006333.	3.2	6
125	Multidrug-resistant Neisseria gonorrhoeae: implications for future treatment strategies. Lancet Infectious Diseases, The, 2018, 18, 599.	9.1	9
126	Impact of stochastically generated heterogeneity in hazard rates on individually randomized vaccine efficacy trials. Clinical Trials, 2018, 15, 207-211.	1.6	11

#	Article	IF	CITATIONS
127	The impact of serotype-specific vaccination on phylodynamic parameters of Streptococcus pneumoniae and the pneumococcal pan-genome. PLoS Pathogens, 2018, 14, e1006966.	4.7	25
128	Preprints: An underutilized mechanism to accelerate outbreak science. PLoS Medicine, 2018, 15, e1002549.	8.4	100
129	The evolution of antibiotic resistance in a structured host population. Journal of the Royal Society Interface, 2018, 15, 20180040.	3.4	49
130	Can antibiotic resistance be reduced by vaccinating against respiratory disease?. Lancet Respiratory Medicine,the, 2018, 6, 820-821.	10.7	14
131	Trends in outpatient antibiotic use and prescribing practice among US older adults, 2011-15: observational study. BMJ: British Medical Journal, 2018, 362, k3155.	2.3	58
132	Measurement of Vaccine Direct Effects Under the Test-Negative Design. American Journal of Epidemiology, 2018, 187, 2686-2697.	3.4	91
133	Why Do Exceptionally Dangerous Gain-of-Function Experiments in Influenza?. Methods in Molecular Biology, 2018, 1836, 589-608.	0.9	14
134	Choices in vaccine trial design in epidemics of emerging infections. PLoS Medicine, 2018, 15, e1002632.	8.4	29
135	Impact of Antimicrobial Treatment for Acute Otitis Media on Carriage Dynamics of Penicillin-Susceptible and Penicillin-Nonsusceptible Streptococcus pneumoniae. Journal of Infectious Diseases, 2018, 218, 1356-1366.	4.0	13
136	Antigenic Variation in <i>Streptococcus pneumoniae</i> PspC Promotes Immune Escape in the Presence of Variant-Specific Immunity. MBio, 2018, 9, .	4.1	24
137	Panproteome-wide analysis of antibody responses to whole cell pneumococcal vaccination. ELife, 2018, 7, .	6.0	26
138	The distribution of antibiotic use and its association with antibiotic resistance. ELife, 2018, 7, .	6.0	132
139	Pneumococcal protein antigen serology varies with age and may predict antigenic profile of colonizing isolates. Journal of Infectious Diseases, 2017, 215, jiw628.	4.0	18
140	Evolution of antibiotic resistance is linked to any genetic mechanism affecting bacterial duration of carriage. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1075-1080.	7.1	133
141	Displacement of sexual partnerships in trials of sexual behavior interventions: A model-based assessment of consequences. Epidemics, 2017, 20, 94-101.	3.0	3
142	Vaccine testing for emerging infections: the case for individual randomisation. Journal of Medical Ethics, 2017, 43, 625-631.	1.8	12
143	Temporally Varying Relative Risks for Infectious Diseases. Epidemiology, 2017, 28, 136-144.	2.7	37
144	Population effect of influenza vaccination under co-circulation of non-vaccine variants and the case for a bivalent A/H3N2 vaccine component. Epidemics, 2017, 19, 74-82.	3.0	4

#	Article	IF	CITATIONS
145	Monitoring the fitness of antiviral-resistant influenza strains during an epidemic: a mathematical modelling study. Lancet Infectious Diseases, The, 2017, 17, 339-347.	9.1	27
146	Diverse evolutionary patterns of pneumococcal antigens identified by pangenome-wide immunological screening. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E357-E366.	7.1	68
147	Immunization, Antibiotic Use, and Pneumococcal Colonization Over a 15-Year Period. Pediatrics, 2017, 140, .	2.1	33
148	Frequency-dependent selection in vaccine-associated pneumococcal population dynamics. Nature Ecology and Evolution, 2017, 1, 1950-1960.	7.8	121
149	Host population structure and treatment frequency maintain balancing selection on drug resistance. Journal of the Royal Society Interface, 2017, 14, 20170295.	3.4	32
150	Improving vaccine trials in infectious disease emergencies. Science, 2017, 357, 153-156.	12.6	28
151	Exploring the role of competition induced by non-vaccine serotypes for herd protection following pneumococcal vaccination. Journal of the Royal Society Interface, 2017, 14, 20170620.	3.4	18
152	Vaccine Effects on Heterogeneity in Susceptibility and Implications for Population Health Management. MBio, 2017, 8, .	4.1	32
153	Underprotection of Unpredictable Statistical Lives Compared to Predictable Ones. Risk Analysis, 2017, 37, 893-904.	2.7	5
154	Shared Genomic Variants: Identification of Transmission Routes Using Pathogen Deep-Sequence Data. American Journal of Epidemiology, 2017, 186, 1209-1216.	3.4	84
155	Pan-serotype Reduction in Progression of Streptococcus pneumoniae to Otitis Media After Rollout of Pneumococcal Conjugate Vaccines. Clinical Infectious Diseases, 2017, 65, 1853-1861.	5.8	23
156	Systematic analysis of protein identity between Zika virus and other arthropod-borne viruses. Bulletin of the World Health Organization, 2017, 95, 517-5251.	3.3	52
157	Using simulation to aid trial design: Ring-vaccination trials. PLoS Neglected Tropical Diseases, 2017, 11, e0005470.	3.0	25
158	Simulations for designing and interpreting intervention trials in infectious diseases. BMC Medicine, 2017, 15, 223.	5.5	64
159	If a Global Catastrophic Biological Risk Materializes, at What Stage Will We Recognize It?. Health Security, 2017, 15, 331-334.	1.8	18
160	Antibiotic Consumption and Antibiotic Resistance Across Organisms, Drugs, and Consumer Groups. Open Forum Infectious Diseases, 2017, 4, S18-S19.	0.9	1
161	Impact of Host Heterogeneity on the Efficacy of Interventions to Reduce <i>Staphylococcus aureus</i> Carriage. Infection Control and Hospital Epidemiology, 2016, 37, 197-204.	1.8	7
162	Zika vaccine trials. Science, 2016, 353, 1094-1095.	12.6	7

#	Article	IF	CITATIONS
163	Observational studies and the difficult quest for causality: lessons from vaccine effectiveness and impact studies. International Journal of Epidemiology, 2016, 45, dyw124.	1.9	82
164	Comment on "Gain-of-Function Research and the Relevance to Clinical Practice― Table 1 Journal of Infectious Diseases, 2016, 214, 1284-1285.	4.0	3
165	Genomic Epidemiology of Gonococcal Resistance to Extended-Spectrum Cephalosporins, Macrolides, and Fluoroquinolones in the United States, 2000–2013. Journal of Infectious Diseases, 2016, 214, 1579-1587.	4.0	186
166	Fractional dosing of yellow fever vaccine to extend supply: a modelling study. Lancet, The, 2016, 388, 2904-2911.	13.7	72
167	How Can Vaccines Contribute to Solving the Antimicrobial Resistance Problem?. MBio, 2016, 7, .	4.1	152
168	Identifying the effect of patient sharing on between-hospital genetic differentiation of methicillin-resistant Staphylococcus aureus. Genome Medicine, 2016, 8, 18.	8.2	20
169	Improving Control of Antibiotic-Resistant Gonorrhea by Integrating Research Agendas Across Disciplines: Key Questions Arising From Mathematical Modeling. Journal of Infectious Diseases, 2016, 213, 883-890.	4.0	38
170	Infective endocarditis and cancer in the elderly. European Journal of Epidemiology, 2016, 31, 41-49.	5.7	22
171	Viral factors in influenza pandemic risk assessment. ELife, 2016, 5, .	6.0	82
172	Population genomic datasets describing the post-vaccine evolutionary epidemiology of Streptococcus pneumoniae. Scientific Data, 2015, 2, 150058.	5.3	67
173	Examining the role of different age groups and of vaccination during the 2012 Minnesota pertussis outbreak. Scientific Reports, 2015, 5, 13182.	3.3	20
174	How could preventive therapy affect the prevalence of drug resistance? Causes and consequences. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140306.	4.0	19
175	Enhancing disease surveillance with novel data streams: challenges and opportunities. EPJ Data Science, 2015, 4, .	2.8	119
176	Estimating the hospitalization burden associated with influenza and respiratory syncytial virus in <scp>N</scp> ew <scp>Y</scp> ork <scp>C</scp> ity, 2003–2011. Influenza and Other Respiratory Viruses, 2015, 9, 225-233.	3.4	46
177	Identification of pneumococcal colonization determinants in the stringent response pathway facilitated by genomic diversity. BMC Genomics, 2015, 16, 369.	2.8	13
178	Defusing a Biological Bomb. Scientific American, 2015, 312, 14-14.	1.0	0
179	Reply to "Studies on Influenza Virus Transmission between Ferrets: the Public Health Risks Revisited― MBio, 2015, 6, .	4.1	12
180	Origin and Proliferation of Multiple-Drug Resistance in Bacterial Pathogens. Microbiology and Molecular Biology Reviews, 2015, 79, 101-116.	6.6	183

#	Article	IF	CITATIONS
181	Sequence tag–based analysis of microbial population dynamics. Nature Methods, 2015, 12, 223-226.	19.0	100
182	Stability of the pneumococcal population structure in Massachusetts as PCV13 was introduced. BMC Infectious Diseases, 2015, 15, 68.	2.9	26
183	Inference of seasonal and pandemic influenza transmission dynamics. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2723-2728.	7.1	133
184	Selective and Genetic Constraints on Pneumococcal Serotype Switching. PLoS Genetics, 2015, 11, e1005095.	3.5	78
185	Carriage burden, multiple colonization and antibiotic pressure promote emergence of resistant vaccine escape pneumococci. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140342.	4.0	31
186	Ebola and beyond. Science, 2015, 348, 46-48.	12.6	18
187	Effect of Serotype on Pneumococcal Competition in a Mouse Colonization Model. MBio, 2015, 6, e00902-15.	4.1	47
188	Antibiotics in agriculture and the risk to human health: how worried should we be?. Evolutionary Applications, 2015, 8, 240-247.	3.1	401
189	The ethics of biosafety considerations in gain-of-function research resulting in the creation of potential pandemic pathogens: TableA1. Journal of Medical Ethics, 2015, 41, 901-908.	1.8	28
190	On the relative role of different age groups in influenza epidemics. Epidemics, 2015, 13, 10-16.	3.0	128
191	Gain-of-function experiments: time for a real debate. Nature Reviews Microbiology, 2015, 13, 58-64.	28.6	49
192	Potential Biases in Estimating Absolute and Relative Case-Fatality Risks during Outbreaks. PLoS Neglected Tropical Diseases, 2015, 9, e0003846.	3.0	170
193	Development, Calibration and Performance of an HIV Transmission Model Incorporating Natural History and Behavioral Patterns: Application in South Africa. PLoS ONE, 2014, 9, e98272.	2.5	20
194	Improving pandemic influenza risk assessment. ELife, 2014, 3, e03883.	6.0	53
195	Changing the Ecology of Pneumococci with Antibiotics and Vaccines. , 2014, , 281-313.		6
196	Ethical Alternatives to Experiments with Novel Potential Pandemic Pathogens. PLoS Medicine, 2014, 11, e1001646.	8.4	106
197	Within-Host Bacterial Diversity Hinders Accurate Reconstruction of Transmission Networks from Genomic Distance Data. PLoS Computational Biology, 2014, 10, e1003549.	3.2	148
198	A Missing Dimension in Measures of Vaccination Impacts. PLoS Pathogens, 2014, 10, e1003849.	4.7	54

#	Article	IF	CITATIONS
199	Moratorium on Research Intended To Create Novel Potential Pandemic Pathogens. MBio, 2014, 5, .	4.1	46
200	The Distribution of Pairwise Genetic Distances: A Tool for Investigating Disease Transmission. Genetics, 2014, 198, 1395-1404.	2.9	43
201	A New Approach to the Analysis of Antibiotic Resistance Data from Hospitals. Microbial Drug Resistance, 2014, 20, 583-590.	2.0	4
202	Epidemiologic data and pathogen genome sequences: a powerful synergy for public health. Genome Biology, 2014, 15, 538.	8.8	97
203	Utilizing Syndromic Surveillance Data for Estimating Levels of Influenza Circulation. American Journal of Epidemiology, 2014, 179, 1394-1401.	3.4	27
204	The US 2009 A(H1N1) Influenza Epidemic. Epidemiology, 2014, 25, 203-206.	2.7	26
205	Age- and Sex-related Risk Factors for Influenza-associated Mortality in the United States Between 1997–2007. American Journal of Epidemiology, 2014, 179, 156-167.	3.4	123
206	Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the USA: a retrospective observational study. Lancet Infectious Diseases, The, 2014, 14, 220-226.	9.1	193
207	Within-Host Whole-Genome Deep Sequencing and Diversity Analysis of Human Respiratory Syncytial Virus Infection Reveals Dynamics of Genomic Diversity in the Absence and Presence of Immune Pressure. Journal of Virology, 2014, 88, 7286-7293.	3.4	53
208	<i>In Vitro</i> Selection of Neisseria gonorrhoeae Mutants with Elevated MIC Values and Increased Resistance to Cephalosporins. Antimicrobial Agents and Chemotherapy, 2014, 58, 6986-6989.	3.2	20
209	Nuanced risk assessment for emerging infectious diseases. Lancet, The, 2014, 383, 189-190.	13.7	24
210	Estimating the Per-Exposure Effect of Infectious Disease Interventions. Epidemiology, 2014, 25, 134-138.	2.7	22
211	Can Limited Scientific Value of Potential Pandemic Pathogen Experiments Justify the Risks?. MBio, 2014, 5, e02008-14.	4.1	9
212	A Modified Janus Cassette (Sweet Janus) to Improve Allelic Replacement Efficiency by High-Stringency Negative Selection in Streptococcus pneumoniae. PLoS ONE, 2014, 9, e100510.	2.5	41
213	The Association of Meningococcal Disease with Influenza in the United States, 1989–2009. PLoS ONE, 2014, 9, e107486.	2.5	45
214	Predictors of indoor absolute humidity and estimated effects on influenza virus survival in grade schools. BMC Infectious Diseases, 2013, 13, 71.	2.9	37
215	Ferret H7N9 flu model questioned. Nature, 2013, 501, 33-33.	27.8	11
216	Oseltamivir Effect on Antibiotic-Treated Lower Respiratory Tract Complications in Virologically Positive Randomized Trial Participants. Clinical Infectious Diseases, 2013, 57, 1368-1369.	5.8	10

#	Article	IF	CITATIONS
217	Real-time influenza forecasts during the 2012–2013 season. Nature Communications, 2013, 4, 2837.	12.8	234
218	Pathogen Diversity and Hidden Regimes of Apparent Competition. American Naturalist, 2013, 181, 12-24.	2.1	41
219	Population genomics of post-vaccine changes in pneumococcal epidemiology. Nature Genetics, 2013, 45, 656-663.	21.4	364
220	Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nature Genetics, 2013, 45, 784-790.	21.4	405
221	Broad Conditions Favor the Evolution of Phase-Variable Loci. MBio, 2013, 4, e00430-12.	4.1	31
222	Comparative Genomics of Recent Shiga Toxin-Producing Escherichia coli O104:H4: Short-Term Evolution of an Emerging Pathogen. MBio, 2013, 4, e00452-12.	4.1	68
223	Streptococcus pneumoniae Capsular Serotype Invasiveness Correlates with the Degree of Factor H Binding and Opsonization with C3b/iC3b. Infection and Immunity, 2013, 81, 354-363.	2.2	83
224	Within-Host Selection Is Limited by an Effective Population of Streptococcus pneumoniae during Nasopharyngeal Colonization. Infection and Immunity, 2013, 81, 4534-4543.	2.2	30
225	Using Pneumococcal Carriage Data to Monitor Postvaccination Changes in Invasive Disease. American Journal of Epidemiology, 2013, 178, 1488-1495.	3.4	60
226	Geographic and Temporal Trends in Antimicrobial Nonsusceptibility in Streptococcus pneumoniae in the United States. Journal of Infectious Diseases, 2013, 208, 1266-1273.	4.0	42
227	Surface Charge of Streptococcus pneumoniae Predicts Serotype Distribution. Infection and Immunity, 2013, 81, 4519-4524.	2.2	54
228	The El Nino-Southern Oscillation (ENSO)-pandemic Influenza connection: Coincident or causal?. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3689-3691.	7.1	36
229	Targeting Imperfect Vaccines against Drug-Resistance Determinants: A Strategy for Countering the Rise of Drug Resistance. PLoS ONE, 2013, 8, e68940.	2.5	40
230	Distinct Effects on Diversifying Selection by Two Mechanisms of Immunity against Streptococcus pneumoniae. PLoS Pathogens, 2012, 8, e1002989.	4.7	43
231	Cholera Modeling. Epidemiology, 2012, 23, 523-530.	2.7	61
232	Niche and Neutral Effects of Acquired Immunity Permit Coexistence of Pneumococcal Serotypes. Science, 2012, 335, 1376-1380.	12.6	163
233	Modelling seasonal variations in the age and incidence of Kawasaki disease to explore possible infectious aetiologies. Proceedings of the Royal Society B: Biological Sciences, 2012, 279, 2736-2743.	2.6	18
234	Vaccine allocation in a declining epidemic. Journal of the Royal Society Interface, 2012, 9, 2798-2803.	3.4	9

#	Article	IF	CITATIONS
235	Impact of More Than a Decade of Pneumococcal Conjugate Vaccine Use on Carriage and Invasive Potential in Native American Communities. Journal of Infectious Diseases, 2012, 205, 280-288.	4.0	92
236	Genomic epidemiology of the <i>Escherichia coli</i> O104:H4 outbreaks in Europe, 2011. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3065-3070.	7.1	262
237	Rates of Acquisition and Clearance of Pneumococcal Serotypes in the Nasopharynges of Children in Kilifi District, Kenya. Journal of Infectious Diseases, 2012, 206, 1020-1029.	4.0	79
238	Reply to Guy et al.: Support for a bottleneck in the 2011 Escherichia coli O104:H4 outbreak in Germany. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3629-E3630.	7.1	2
239	Patient sharing and population genetic structure of methicillin-resistant <i>Staphylococcus aureus</i> . Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6763-6768.	7.1	22
240	Comment on "Seroevidence for H5N1 Influenza Infections in Humans: Meta-Analysisâ€: Science, 2012, 336, 1506-1506.	12.6	31
241	Estimating Rates of Carriage Acquisition and Clearance and Competitive Ability for Pneumococcal Serotypes in Kenya With a Markov Transition Model. Epidemiology, 2012, 23, 510-519.	2.7	79
242	Improving the Estimation of Influenza-Related Mortality Over a Seasonal Baseline. Epidemiology, 2012, 23, 829-838.	2.7	140
243	Rethinking Biosafety in Research on Potential Pandemic Pathogens. MBio, 2012, 3, .	4.1	31
244	Reply to â€~Declining adherence as a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial'. Aids, 2012, 26, 2262-2263.	2.2	0
245	Pneumococcal Carriage and Antibiotic Resistance in Young Children Before 13-valent Conjugate Vaccine. Pediatric Infectious Disease Journal, 2012, 31, 249-254.	2.0	71
246	Apparent declining efficacy in randomized trials. Aids, 2012, 26, 123-126.	2.2	35
247	Negative Control Exposures in Epidemiologic Studies. Epidemiology, 2012, 23, 351-352.	2.7	18
248	Serotype replacement after pneumococcal vaccination – Authors' reply. Lancet, The, 2012, 379, 1388-1389.	13.7	8
249	Pneumococcal sequence type replacement among American Indian children: A comparison of pre- and routine-PCV7 eras. Vaccine, 2012, 30, 2376-2381.	3.8	18
250	Secular Trends in Helicobacter pylori Seroprevalence in Adults in the United States: Evidence for Sustained Race/Ethnic Disparities. American Journal of Epidemiology, 2012, 175, 54-59.	3.4	128
251	The Prevalence and Risk Factors for Pneumococcal Colonization of the Nasopharynx among Children in Kilifi District, Kenya. PLoS ONE, 2012, 7, e30787.	2.5	96
252	Searching for Sharp Drops in the Incidence of Pandemic A/H1N1 Influenza by Single Year of Age. PLoS ONE, 2012, 7, e42328.	2.5	32

#	Article	IF	CITATIONS
253	Factors Related to Increasing Prevalence of Resistance to Ciprofloxacin and Other Antimicrobial Drugs in <i>Neisseria gonorrhoeae</i> , United States. Emerging Infectious Diseases, 2012, 18, 1290-1297.	4.3	44
254	Evolution, Safety, and Highly Pathogenic Influenza Viruses. Science, 2012, 336, 1529-1531.	12.6	31
255	Clonal replacement among 19A Streptococcus pneumoniae in Massachusetts, prior to 13 valent conjugate vaccination. Vaccine, 2011, 29, 8877-8881.	3.8	40
256	Serotype replacement in disease after pneumococcal vaccination. Lancet, The, 2011, 378, 1962-1973.	13.7	833
257	Vaccine production, distribution, access, and uptake. Lancet, The, 2011, 378, 428-438.	13.7	97
258	Shortcomings of Vitamin D-Based Model Simulations of Seasonal Influenza. PLoS ONE, 2011, 6, e20743.	2.5	40
259	Prediction of Serotypes Causing Invasive Pneumococcal Disease in Unvaccinated and Vaccinated Populations. Epidemiology, 2011, 22, 199-207.	2.7	35
260	Carried Pneumococci in Massachusetts Children. Pediatric Infectious Disease Journal, 2011, 30, 302-308.	2.0	55
261	Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nature Genetics, 2011, 43, 482-486.	21.4	403
262	Changes in severity of 2009 pandemic A/H1N1 influenza in England: a Bayesian evidence synthesis. BMJ: British Medical Journal, 2011, 343, d5408-d5408.	2.3	71
263	Is methicillin-resistant Staphylococcus aureus replacing methicillin-susceptible S. aureus?. Journal of Antimicrobial Chemotherapy, 2011, 66, 2199-2214.	3.0	63
264	Absolute Humidity and Pandemic Versus Epidemic Influenza. American Journal of Epidemiology, 2011, 173, 127-135.	3.4	178
265	Oseltamivir and Risk of Lower Respiratory Tract Complications in Patients With Flu Symptoms: A Meta-analysis of Eleven Randomized Clinical Trials. Clinical Infectious Diseases, 2011, 53, 277-279.	5.8	110
266	Reply to Cochrane Neuraminidase Inhibitors Review Team. Clinical Infectious Diseases, 2011, 53, 1303-1304.	5.8	4
267	Predicting the Epidemic Sizes of Influenza A/H1N1, A/H3N2, and B: A Statistical Method. PLoS Medicine, 2011, 8, e1001051.	8.4	153
268	S128 Highly invasive capsular serotypes of Streptococcus pneumoniae bind high levels of Factor H and are resistant to complement and phagocytosis. Thorax, 2011, 66, A59-A59.	5.6	0
269	Improving the evidence base for decision making during a pandemic: the example of 2009 influenza A/H1N1. Biosecurity and Bioterrorism, 2011, 9, 89-115.	1.2	97
270	Estimating Incidence Curves of Several Infections Using Symptom Surveillance Data. PLoS ONE, 2011, 6, e23380.	2.5	9

#	Article	IF	CITATIONS
271	Oseltamivir for treatment and prevention of pandemic influenza A/H1N1 virus infection in households, Milwaukee, 2009. BMC Infectious Diseases, 2010, 10, 211.	2.9	43
272	Preâ€dispensing of antivirals to highâ€risk individuals in an influenza pandemic. Influenza and Other Respiratory Viruses, 2010, 4, 101-112.	3.4	6
273	Student Behavior during a School Closure Caused by Pandemic Influenza A/H1N1. PLoS ONE, 2010, 5, e10425.	2.5	40
274	Viral Shedding and Clinical Illness in Naturally Acquired Influenza Virus Infections. Journal of Infectious Diseases, 2010, 201, 1509-1516.	4.0	258
275	What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of <i>Streptococcus pneumoniae</i> ?. Journal of the Royal Society Interface, 2010, 7, 905-919.	3.4	83
276	Distribution of vaccine/antivirals and the â€~least spread line' in a stratified population. Journal of the Royal Society Interface, 2010, 7, 755-764.	3.4	44
277	Association of Serotype with Risk of Death Due to Pneumococcal Pneumonia: A Metaâ€Analysis. Clinical Infectious Diseases, 2010, 51, 692-699.	5.8	297
278	Optimizing infectious disease interventions during an emerging epidemic. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 923-928.	7.1	154
279	Absolute Humidity and the Seasonal Onset of Influenza in the Continental United States. PLoS Biology, 2010, 8, e1000316.	5.6	513
280	Studies Needed to Address Public Health Challenges of the 2009 H1N1 Influenza Pandemic: Insights from Modeling. PLoS Medicine, 2010, 7, e1000275.	8.4	75
281	Negative Controls. Epidemiology, 2010, 21, 383-388.	2.7	923
282	Mobile Messaging as Surveillance Tool during Pandemic (H1N1) 2009, Mexico. Emerging Infectious Diseases, 2010, 16, 1488-1489.	4.3	16
283	Quantifying Interhospital Patient Sharing as a Mechanism for Infectious Disease Spread. Infection Control and Hospital Epidemiology, 2010, 31, 1160-1169.	1.8	65
284	The role of complement in innate and adaptive immunity to pneumococcal colonization and sepsis in a murine model. Vaccine, 2010, 28, 681-685.	3.8	32
285	Re-emergence of the type 1 pilus among Streptococcus pneumoniae isolates in Massachusetts, USA. Vaccine, 2010, 28, 4842-4846.	3.8	60
286	Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine, 2010, 29, 283-288.	3.8	112
287	Quantifying Child Mortality Reductions Related to Measles Vaccination. PLoS ONE, 2010, 5, e13842.	2.5	21

#	Article	IF	CITATIONS
289	Time from Illness Onset to Death, 1918 Influenza and Pneumococcal Pneumonia. Emerging Infectious Diseases, 2009, 15, 346-347.	4.3	31
290	Understanding Australia's influenza pandemic policy on the strategic use of the antiviral drug stockpile. Medical Journal of Australia, 2009, 191, 136-137.	1.7	7
291	Influenza seasonality: Lifting the fog. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3645-3646.	7.1	197
292	Impaired Innate and Adaptive Immunity to <i>Streptococcus pneumoniae</i> and Its Effect on Colonization in an Infant Mouse Model. Infection and Immunity, 2009, 77, 1613-1622.	2.2	63
293	Managing and Reducing Uncertainty in an Emerging Influenza Pandemic. New England Journal of Medicine, 2009, 361, 112-115.	27.0	172
294	Estimates of the Prevalence of Pandemic (H1N1) 2009, United States, April–July 2009. Emerging Infectious Diseases, 2009, 15, 2004-2007.	4.3	290
295	Hedging against Antiviral Resistance during the Next Influenza Pandemic Using Small Stockpiles of an Alternative Chemotherapy. PLoS Medicine, 2009, 6, e1000085.	8.4	72
296	The Severity of Pandemic H1N1 Influenza in the United States, from April to July 2009: A Bayesian Analysis. PLoS Medicine, 2009, 6, e1000207.	8.4	262
297	Pneumococcal Capsular Polysaccharide Structure Predicts Serotype Prevalence. PLoS Pathogens, 2009, 5, e1000476.	4.7	264
298	Continued Impact of Pneumococcal Conjugate Vaccine on Carriage in Young Children. Pediatrics, 2009, 124, e1-e11.	2.1	258
299	The Pneumococcal Pilus Predicts the Absence of <i>Staphylococcus aureus</i> Coâ€Colonization in Pneumococcal Carriers. Clinical Infectious Diseases, 2009, 48, 760-763.	5.8	46
300	Reconstructing influenza incidence by deconvolution of daily mortality time series. Proceedings of the United States of America, 2009, 106, 21825-21829.	7.1	89
301	Epidemiology and risk factors for Staphylococcus aureuscolonization in children in the post-PCV7 era. BMC Infectious Diseases, 2009, 9, 110.	2.9	48
302	Estimation of the reproductive number and the serial interval in early phase of the 2009 influenza A/H1N1 pandemic in the USA. Influenza and Other Respiratory Viruses, 2009, 3, 267-276.	3.4	226
303	Exploring the relationship between incidence and the average age of infection during seasonal epidemics. Journal of Theoretical Biology, 2009, 260, 175-185.	1.7	12
304	Reproductive numbers, epidemic spread and control in a community of households. Mathematical Biosciences, 2009, 221, 11-25.	1.9	42
305	No coexistence for free: Neutral null models for multistrain pathogens. Epidemics, 2009, 1, 2-13.	3.0	130
306	How to maintain surveillance for novel influenza A H1N1 when there are too many cases to count. Lancet, The, 2009, 374, 1209-1211.	13.7	87

#	Article	IF	CITATIONS
307	Predispensing of Antivirals to High-Risk Individuals in an Influenza Pandemic. PLOS Currents, 2009, 1, RRN1007.	1.4	3
308	The severity of pandemic H1N1 influenza in the United States, April – July 2009. PLOS Currents, 2009, 1, RRN1042.	1.4	35
309	Antiviral usage for H1N1 treatment: pros, cons and an argument for broader prescribing guidelines in the United States. PLOS Currents, 2009, 1, RRN1122.	1.4	6
310	H1N1 vaccination and adults with underlying health conditions in the US. PLOS Currents, 2009, 1, RRN1132.	1.4	3
311	Absolute Humidity and the Seasonal Onset of Influenza in the Continental US. PLOS Currents, 2009, 1, RRN1138.	1.4	31
312	Use of Cumulative Incidence of Novel Influenza A/H1N1 in Foreign Travelers to Estimate Lower Bounds on Cumulative Incidence in Mexico. PLoS ONE, 2009, 4, e6895.	2.5	29
313	Generation interval contraction and epidemic data analysis. Mathematical Biosciences, 2008, 213, 71-79.	1.9	92
314	Protection against Nasopharyngeal Colonization by <i>Streptococcus pneumoniae</i> Is Mediated by Antigen-Specific CD4 ⁺ T Cells. Infection and Immunity, 2008, 76, 2678-2684.	2.2	82
315	In Vitro Bactericidal Activity of <i>Streptococcus pneumoniae</i> and Bactericidal Susceptibility of <i>Staphylococcus aureus</i> Strains Isolated from Cocolonized versus Noncocolonized Children. Journal of Clinical Microbiology, 2008, 46, 747-749.	3.9	14
316	Too Little of a Good Thing. Epidemiology, 2008, 19, 588-589.	2.7	3
317	Epidemiologic Evidence for Serotypeâ€Specific Acquired Immunity to Pneumococcal Carriage. Journal of Infectious Diseases, 2008, 197, 1511-1518.	4.0	117
318	Interleukin-17A Mediates Acquired Immunity to Pneumococcal Colonization. PLoS Pathogens, 2008, 4, e1000159.	4.7	422
319	Does Pneumococcal Conjugate Vaccine Influence <i>Staphylococcus aureus</i> Carriage in Children?. Clinical Infectious Diseases, 2008, 47, 289-291.	5.8	16
320	Seasonality of Antibioticâ€Resistant <i>Streptococcus pneumoniae</i> That Causes Acute Otitis Media: A Clue for an Antibioticâ€Restriction Policy?. Journal of Infectious Diseases, 2008, 197, 1094-1102.	4.0	93
321	The Effect of Antiretroviral Therapy on Secondary Transmission of HIV among Men Who Have Sex with Men. Clinical Infectious Diseases, 2007, 44, 1115-1122.	5.8	48
322	How generation intervals shape the relationship between growth rates and reproductive numbers. Proceedings of the Royal Society B: Biological Sciences, 2007, 274, 599-604.	2.6	1,045
323	Serum Antipneumococcal Antibodies and Pneumococcal Colonization in Adults with Chronic Obstructive Pulmonary Disease. Journal of Infectious Diseases, 2007, 196, 928-935.	4.0	28
324	Antiviral Resistance and the Control of Pandemic Influenza. PLoS Medicine, 2007, 4, e15.	8.4	182

#	Article	IF	CITATIONS
325	Estimating Variability in the Transmission of Severe Acute Respiratory Syndrome to Household Contacts in Hong Kong, China. American Journal of Epidemiology, 2007, 166, 355-363.	3.4	50
326	Public health interventions and epidemic intensity during the 1918 influenza pandemic. Proceedings of the United States of America, 2007, 104, 7582-7587.	7.1	605
327	Diversity and Antibiotic Resistance among Nonvaccine Serotypes ofStreptococcus pneumoniaeCarriage Isolates in the Post–Heptavalent Conjugate Vaccine Era. Journal of Infectious Diseases, 2007, 195, 347-352.	4.0	127
328	Strain Characteristics ofStreptococcus pneumoniaeCarriage and Invasive Disease Isolates during a Clusterâ€Randomized Clinical Trial of the 7â€Valent Pneumococcal Conjugate Vaccine. Journal of Infectious Diseases, 2007, 196, 1221-1227.	4.0	56
329	Antibody-Independent, CD4 ⁺ T-Cell-Dependent Protection against Pneumococcal Colonization Elicited by Intranasal Immunization with Purified Pneumococcal Proteins. Infection and Immunity, 2007, 75, 5460-5464.	2.2	86
330	Association of the Pneumococcal Pilus with Certain Capsular Serotypes but Not with Increased Virulence. Journal of Clinical Microbiology, 2007, 45, 1684-1689.	3.9	78
331	SpxB Is a Suicide Gene of <i>Streptococcus pneumoniae</i> and Confers a Selective Advantage in an In Vivo Competitive Colonization Model. Journal of Bacteriology, 2007, 189, 6532-6539.	2.2	97
332	Age- and Serogroup-Related Differences in Observed Durations of Nasopharyngeal Carriage of Penicillin-Resistant Pneumococci. Journal of Clinical Microbiology, 2007, 45, 948-952.	3.9	113
333	Patterns of antigenic diversity and the mechanisms that maintain them. Journal of the Royal Society Interface, 2007, 4, 787-802.	3.4	120
334	Little Evidence for Genetic Susceptibility to Influenza A (H5N1) from Family Clustering Data. Emerging Infectious Diseases, 2007, 13, 1074-1076.	4.3	31
335	Inefficient Cytotoxic T Lymphocyte–Mediated Killing of HIV-1–Infected Cells In Vivo. PLoS Biology, 2006, 4, e90.	5.6	147
336	Pandemic Influenza: Risk of Multiple Introductions and the Need to Prepare for Them. PLoS Medicine, 2006, 3, e135.	8.4	37
337	How Do Antimicrobial Agents Lead to Resistance in Pathogens Causing Acute Respiratory Tract Infections?. Infectious Diseases in Clinical Practice, 2006, 14, S6-S10.	0.3	Ο
338	Multiple Outbreaks and Flu Containment Plans. Science, 2006, 312, 845b-845b.	12.6	5
339	Interference between Streptococcus pneumoniae and Staphylococcus aureus : In Vitro Hydrogen Peroxide-Mediated Killing by Streptococcus pneumoniae. Journal of Bacteriology, 2006, 188, 4996-5001.	2.2	172
340	Mechanisms by Which Antibiotics Promote Dissemination of Resistant Pneumococci in Human Populations. American Journal of Epidemiology, 2006, 163, 160-170.	3.4	48
341	Incremental Increase in Fitness Cost with Increased βâ€Lactam Resistance in Pneumococci Evaluated by Competition in an Infant Rat Nasal Colonization Model. Journal of Infectious Diseases, 2006, 193, 1296-1303.	4.0	63
342	The Influence of Hitchhiking and Deleterious Mutation Upon Asexual Mutation Rates. Genetics, 2006, 173, 461-472.	2.9	18

#	Article	IF	CITATIONS
343	Antibody-Independent, Interleukin-17A-Mediated, Cross-Serotype Immunity to Pneumococci in Mice Immunized Intranasally with the Cell Wall Polysaccharide. Infection and Immunity, 2006, 74, 2187-2195.	2.2	156
344	Upgrading antibiotic use within a class: Tradeoff between resistance and treatment success. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9655-9660.	7.1	46
345	Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7042-7047.	7.1	107
346	Are Anticapsular Antibodies the Primary Mechanism of Protection against Invasive Pneumococcal Disease?. PLoS Medicine, 2005, 2, e15.	8.4	115
347	Modeling Community- and Individual-Level Effects of Child-Care Center Attendance on Pneumococcal Carriage. Clinical Infectious Diseases, 2005, 40, 1215-1222.	5.8	59
348	Serum Serotype‧pecific Pneumococcal Anticapsular Immunoglobulin G Concentrations after Immunization with a 9â€Valent Conjugate Pneumococcal Vaccine Correlate with Nasopharyngeal Acquisition of Pneumococcus. Journal of Infectious Diseases, 2005, 192, 367-376.	4.0	146
349	CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4848-4853.	7.1	321
350	Capsule Homology Does Not Increase the Frequency of Transformation of Linked Penicillin Binding Proteins PBP 1a and PBP 2x in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy, 2005, 49, 1591-1592.	3.2	2
351	Ethics of Rationing the Flu Vaccine. Science, 2005, 307, 41b-41b.	12.6	5
352	Antibodies to Conserved Pneumococcal Antigens Correlate with, but Are Not Required for, Protection against Pneumococcal Colonization Induced by Prior Exposure in a Mouse Model. Infection and Immunity, 2005, 73, 7043-7046.	2.2	64
353	Alert Threshold Algorithms and Malaria Epidemic Detection. Emerging Infectious Diseases, 2004, 10, 1220-1226.	4.3	45
354	From The Cover: Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 13285-13290.	7.1	330
355	Invited Commentary: Real-Time Tracking of Control Measures for Emerging Infections. American Journal of Epidemiology, 2004, 160, 517-519.	3.4	17
356	Age-Specific Immunoglobulin C (IgC) and IgA to Pneumococcal Protein Antigens in a Population in Coastal Kenya. Infection and Immunity, 2004, 72, 3331-3335.	2.2	38
357	Single-Step Capsular Transformation and Acquisition of Penicillin Resistance in Streptococcus pneumoniae. Journal of Bacteriology, 2004, 186, 3447-3452.	2.2	44
358	Projected Benefits of Active Surveillance for Vancomycinâ€Resistant Enterococci in Intensive Care Units. Clinical Infectious Diseases, 2004, 38, 1108-1115.	5.8	94
359	The analysis of hospital infection data using hidden Markov models. Biostatistics, 2004, 5, 223-237.	1.5	160
360	Transmissibility of 1918 pandemic influenza. Nature, 2004, 432, 904-906.	27.8	698

#	Article	IF	CITATIONS
361	Weather-based prediction of Plasmodium falciparum malaria in epidemic-prone regions of Ethiopia II. Weather-based prediction systems perform comparably to early detection systems in identifying times for interventions. Malaria Journal, 2004, 3, 44.	2.3	69
362	Weather-based prediction of Plasmodium falciparum malaria in epidemic-prone regions of Ethiopia I. Patterns of lagged weather effects reflect biological mechanisms. Malaria Journal, 2004, 3, 41.	2.3	164
363	Effect of human leukocyte antigen heterozygosity on infectious disease outcome: The need for allele-specific measures. BMC Medical Genetics, 2003, 4, 2.	2.1	38
364	Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nature Medicine, 2003, 9, 424-430.	30.7	206
365	Transmission Dynamics and Control of Severe Acute Respiratory Syndrome. Science, 2003, 300, 1966-1970.	12.6	1,281
366	Multiple equilibria: Tuberculosis transmission require unrealistic assumptions. Theoretical Population Biology, 2003, 63, 169-170.	1.1	29
367	Antibiotic resistance—the interplay between antibiotic use in animals and human beings. Lancet Infectious Diseases, The, 2003, 3, 47-51.	9.1	227
368	Construction of Otherwise Isogenic Serotype 6B, 7F, 14, and 19F Capsular Variants of Streptococcus pneumoniae Strain TIGR4. Applied and Environmental Microbiology, 2003, 69, 7364-7370.	3.1	74
369	Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 1966-1971.	7.1	627
370	Controlâ€Group Selection Importance in Studies of Antimicrobial Resistance: Examples Applied toPseudomonas aeruginosa,Enterococci, andEscherichia coli. Clinical Infectious Diseases, 2002, 34, 1558-1563.	5.8	163
371	Projection of the Future Dimensions and Costs of the Genital Herpes Simplex Type 2 Epidemic in the United States. Sexually Transmitted Diseases, 2002, 29, 608-622.	1.7	48
372	Potential Benefits of a Serodiagnostic Test for Herpes Simplex Virus Type 1 (HSV-1) to Prevent Neonatal HSV-1 Infection. Sexually Transmitted Diseases, 2002, 29, 399-405.	1.7	8
373	Antibiotics in agriculture: When is it time to close the barn door?. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 5752-5754.	7.1	115
374	Antimicrobial Use and Antimicrobial Resistance: A Population Perspective. Emerging Infectious Diseases, 2002, 8, 347-354.	4.3	407
375	Historical Intensity of Natural Selection for Resistance to Tuberculosis. Genetics, 2002, 161, 1599-1607.	2.9	43
376	The rise and fall of antimicrobial resistance. Trends in Microbiology, 2001, 9, 438-444.	7.7	165
377	Intranasal Immunization with Killed Unencapsulated Whole Cells Prevents Colonization and Invasive Disease by Capsulated Pneumococci. Infection and Immunity, 2001, 69, 4870-4873.	2.2	162
378	Measuring and Interpreting Associations between Antibiotic Use and Penicillin Resistance in Streptococcus pneumoniae. Clinical Infectious Diseases, 2001, 32, 1044-1054.	5.8	117

#	Article	IF	CITATIONS
379	Visualizing Pneumococcal Infections in the Lungs of Live Mice Using Bioluminescent Streptococcus pneumoniaeTransformed with a Novel Gram-Positive luxTransposon. Infection and Immunity, 2001, 69, 3350-3358.	2.2	256
380	MICROBIOLOGY: Bacterial Population Genetics and Disease. Science, 2001, 292, 59-60.	12.6	9
381	Concentration-Dependent Selection of Small Phenotypic Differences in TEM β-Lactamase-Mediated Antibiotic Resistance. Antimicrobial Agents and Chemotherapy, 2000, 44, 2485-2491.	3.2	114
382	The epidemiology of antibiotic resistance in hospitals: Paradoxes and prescriptions. Proceedings of the United States of America, 2000, 97, 1938-1943.	7.1	359
383	Effects of Antiviral Usage on Transmission Dynamics of Herpes Simplex Virus Type 1 and on Antiviral Resistance: Predictions of Mathematical Models. Antimicrobial Agents and Chemotherapy, 2000, 44, 2824-2835.	3.2	18
384	Interpreting Results from Trials of Pneumococcal Conjugate Vaccines: A Statistical Test for Detecting Vaccine-induced Increases in Carriage of Nonvaccine Serotypes. American Journal of Epidemiology, 2000, 154, 85-92.	3.4	57
385	Competition among Streptococcus pneumoniae for intranasal colonization in a mouse model. Vaccine, 2000, 18, 2895-2901.	3.8	110
386	Bacterial Vaccines and Serotype Replacement: Lessons from <i>Haemophilus influenzae</i> and Prospects for <i>Streptococcus pneumoniae</i> . Emerging Infectious Diseases, 1999, 5, 336-345.	4.3	264
387	Population Biology, Evolution, and Infectious Disease: Convergence and Synthesis. Science, 1999, 283, 806-809.	12.6	219
388	The Population Genetics of Antibiotic Resistance II: Analytic Theory for Sustained Populations of Bacteria in a Community of Hosts. Theoretical Population Biology, 1998, 53, 152-165.	1.1	42
389	Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. International Journal of Tuberculosis and Lung Disease, 1998, 2, 187-99.	1.2	89
390	The Population Genetics of Antibiotic Resistance. Clinical Infectious Diseases, 1997, 24, S9-S16.	5.8	267
391	Evaluating treatment protocols to prevent antibiotic resistance. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 12106-12111.	7.1	441
392	TRANSMISSION RATES AND HIV VIRULENCE: COMMENTS TO MASSAD. Evolution; International Journal of Organic Evolution, 1997, 51, 319-320.	2.3	8
393	Transmission Rates and HIV Virulence: Comments to Massad. Evolution; International Journal of Organic Evolution, 1997, 51, 319.	2.3	2
394	Virulence and transmissibility of pathogens: what is the relationship?. Trends in Microbiology, 1997, 5, 31-37.	7.7	295
395	Vaccination against colonizing bacteria with multiple serotypes. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 6571-6576.	7.1	219
396	The population dynamics of antimicrobial chemotherapy. Antimicrobial Agents and Chemotherapy, 1997, 41, 363-373.	3.2	219

#	Article	IF	CITATIONS
397	The Withinâ€Host Population Dynamics of Antibacterial Chemotherapy: Conditions for the Evolution of Resistance. Novartis Foundation Symposium, 1997, 207, 112-130.	1.1	6
398	THE EVOLUTION OF VIRULENCE IN PATHOGENS WITH VERTICAL AND HORIZONTAL TRANSMISSION. Evolution; International Journal of Organic Evolution, 1996, 50, 1729-1741.	2.3	210
399	Virulence and transmission modes of two microsporidia in <i>Daphnia magna</i> . Parasitology, 1995, 111, 133-142.	1.5	62
400	HOST POPULATION STRUCTURE AND THE EVOLUTION OF VIRULENCE: A "LAW OF DIMINISHING RETURNS― Evolution; International Journal of Organic Evolution, 1995, 49, 743-748.	2.3	25
401	The evolution of virulence in sexually transmitted HIV/AIDS. Journal of Theoretical Biology, 1995, 174, 427-440.	1.7	88
402	Host Population Structure and the Evolution of Virulence: A "Law of Diminishing Returns". Evolution; International Journal of Organic Evolution, 1995, 49, 743.	2.3	84
403	Decreased Infectivity Following BNT162b2 Vaccination. SSRN Electronic Journal, 0, , .	0.4	11
404	Effectiveness of BNT162b2 mRNA COVID-19 Vaccine Against SARS-CoV-2 Variant Beta (B.1.351) Among Persons Identified Through Contact Tracing in Israel. SSRN Electronic Journal, 0, , .	0.4	2